Search

Your search keyword '"Copelan, Edward A."' showing total 850 results
Start Over Author "Copelan, Edward A." Search Limiters Available in Library Collection
850 results on '"Copelan, Edward A."'

1. Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.

Author

Boyiadzis, Michael, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad, Aljurf, Mahmoud, Bacher, Ulrike, Badar, Talha, Badawy, Sherif, Battiwalla, Minoo, Bejanyan, Nelli, Bhatt, Vijaya, Brown, Valerie, Castillo, Paul, Cerny, Jan, Copelan, Edward, Craddock, Charles, Dholaria, Bhagirathbhai, Perez, Miguel, Ebens, Christen, Gale, Robert, Ganguly, Siddhartha, Gowda, Lohith, Grunwald, Michael, Hashmi, Shahrukh, Hildebrandt, Gerhard, Iqbal, Madiha, Jamy, Omer, Kharfan-Dabaja, Mohamed, Khera, Nandita, Lazarus, Hillard, Lin, Richard, Modi, Dipenkumar, Nathan, Sunita, Nishihori, Taiga, Patel, Sagar, Pawarode, Attaphol, Saber, Wael, Sharma, Akshay, Solh, Melhem, Wagner, John, Wang, Trent, Williams, Kirsten, Wirk, Baldeep, Zeidan, Amer, Hourigan, Christopher, Litzow, Mark, Kebriaei, Partow, de Lima, Marcos, Page, Kristin, Weisdorf, Daniel, and Winestone, Lena

Subjects
Adult, Humans, Transplantation, Homologous, Transplantation Conditioning, Neoplasm Recurrence, Local, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Retrospective Studies
Abstract

We investigated the impact of the number of induction/consolidation cycles on outcomes of 3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo-HCT) between 2008 and 2019. Patients received allo-HCT using myeloablative (MAC) or reduced-intensity (RIC) conditioning in first complete remission (CR) or with primary induction failure (PIF). Patients who received MAC allo-HCT in CR after 1 induction cycle had 1.3-fold better overall survival (OS) than 2 cycles to CR and 1.47-fold better than ≥3 cycles. OS after CR in 2 or ≥3 cycles was similar. Relapse risk was 1.65-fold greater in patients receiving ≥3 cycles to achieve CR. After RIC allo-HCT, the number of induction cycles to CR did not affect OS. Compared to CR in 1 cycle, relapse risk was 1.24-1.41-fold greater in patients receiving 2 or ≥3 cycles. For patients receiving only 1 cycle to CR, consolidation therapy prior to MAC allo-HCT was associated with improved OS vs. no consolidation therapy. Detectable MRD at the time of MAC allo-HCT did not impact outcomes while detectable MRD preceding RIC allo-HCT was associated with an increased risk of relapse. For allo-HCT in PIF, OS was significantly worse than allo-HCT in CR after 1-3 cycles.

Published
2023

2. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

Author

Wieduwilt, Matthew J, Metheny, Leland, Zhang, Mei-Jie, Wang, Hai-Lin, Estrada-Merly, Noel, Marks, David I, Al-Homsi, A Samar, Muffly, Lori, Chao, Nelson J, Rizzieri, David, Gale, Robert Peter, Gadalla, Shahinaz M, Cairo, Mitchell S, Mussetti, Alberto, Gore, Steven D, Bhatt, Vijaya Raj, Patel, Sagar S, Michelis, Fotios V, Inamoto, Yoshihiro, Badawy, Sherif M, Copelan, Edward, Palmisiano, Neil, Kharfan-Dabaja, Mohamed A, Lazarus, Hillard M, Ganguly, Siddhartha, Bredeson, Christopher N, Perez, Miguel Angel Diaz, Cassaday, Ryan, Savani, Bipin N, Ballen, Karen Kuhn, Martino, Rodrigo, Wirk, Baldeep, Bacher, Ulrike, Aljurf, Mahmoud, Bashey, Asad, Murthy, Hemant S, Yared, Jean A, Aldoss, Ibrahim, Farhadfar, Nosha, Liu, Hongtao, Abdel-Azim, Hisham, Waller, Edmund K, Solh, Melhem, Seftel, Matthew, van der Poel, Marjolein WM, Grunwald, Michael Richard, Liesveld, Jane L, Kamble, Rammurti T, McGuirk, Joseph P, Munker, Reinhold, Cahn, Jean-Yves, Lee, Jong Wook, Freytes, Cesar O, Krem, Maxwell, Winestone, Lena E, Gergis, Usama, Nathan, Sunita, Olsson, Richard F, Verdonck, Leo F, Sharma, Akshay, Ringden, Olle, Friend, Brian D, Cerny, Jan, Choe, Hannah K, Chhabra, Saurabh, Nishihori, Taiga, Seo, Sachiko, George, Biju, Baxter-Lowe, Lee Ann, Hildebrandt, Gerhard C, de Lima, Marcos, Litzow, Mark R, Kebriaei, Partow, Hourigan, Christopher S, Abid, Muhammad Bilal, Weisdorf, Daniel J, and Saber, Wael

Subjects
Rare Diseases, Cancer, Pediatric, Pediatric Cancer, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Hematology, Stem Cell Research, Transplantation, Good Health and Well Being, Fetal Blood, Hematopoietic Stem Cell Transplantation, Humans, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Siblings, Unrelated Donors
Abstract

The role of haploidentical hematopoietic cell transplantation (HCT) using posttransplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariable analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) among haploidentical HCTs using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD), 7 /8 HLA-MUD, or umbilical cord blood (UCB) HCT. Comparing haploidentical HCT to MSD HCT, we found that OS, leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and acute graft-versus-host disease (aGVHD) were not different but chronic GVHD (cGVHD) was higher in MSD HCT. Compared with MUD HCT, OS, LFS, and relapse were not different, but MUD HCT had increased NRM (hazard ratio [HR], 1.42; P = .02), grade 3 to 4 aGVHD (HR, 1.59; P = .005), and cGVHD. Compared with 7/8 UD HCT, LFS and relapse were not different, but 7/8 UD HCT had worse OS (HR, 1.38; P = .01) and increased NRM (HR, 2.13; P ≤ .001), grade 3 to 4 aGVHD (HR, 1.86; P = .003), and cGVHD (HR, 1.72; P ≤ .001). Compared with UCB HCT, late OS, late LFS, relapse, and cGVHD were not different but UCB HCT had worse early OS (≤18 months; HR, 1.93; P < .001), worse early LFS (HR, 1.40; P = .007) and increased incidences of NRM (HR, 2.08; P < .001) and grade 3 to 4 aGVHD (HR, 1.97; P < .001). Haploidentical HCT using PTCy showed no difference in survival but less GVHD compared with traditional MSD and MUD HCT and is the preferred alternative donor HCT option for adults with ALL in complete remission.

Published
2022

3. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis

Author

Jimenez Jimenez, Antonio M, De Lima, Marcos, Komanduri, Krishna V, Wang, Trent P, Zhang, Mei-Jie, Chen, Karen, Abdel-Azim, Hisham, Abid, Muhammad Bilal, Aljurf, Mahmoud, Alkhateeb, Hassan, Assal, Amer, Bacher, Ulrike, Baron, Frédéric, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Copelan, Edward, DeFilipp, Zachariah, Perez, Miguel Angel Diaz, Elsawy, Mahmoud, Gale, Robert Peter, George, Biju, Grunwald, Michael R, Hildebrandt, Gerhard C, Hogan, William J, Kanakry, Christopher G, Kansagra, Ankit, Kharfan-Dabaja, Mohamed A, Khera, Nandita, Krem, Maxwell M, Lazaryan, Aleksandr, Maakaron, Joseph, Martino, Rodrigo, McGuirk, Joseph, Michelis, Fotios V, Milone, Giuseppe, Mishra, Asmita, Murthy, Hemant S, Mussetti, Alberto, Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F, Palmisiano, Neil, Patel, Sagar, Saad, Ayman, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Verdonck, Leo F, Wirk, Baldeep, Yared, Jean A, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S, Saber, Wael, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Genetics, Transplantation, Pediatric Research Initiative, Childhood Leukemia, Stem Cell Research, Cancer, Clinical Research, Pediatric Cancer, Rare Diseases, Pediatric, Stem Cell Research - Nonembryonic - Human, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, Good Health and Well Being, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Retrospective Studies, Risk Assessment, Transplantation Conditioning, Transplantation, Homologous, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Oncology and carcinogenesis
Abstract

Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, between 2013 and 2017. Patients were stratified according to aELN into three groups: favorable (Fav, N = 181), intermediate (IM, N = 1185), and adverse (Adv, N = 923). Univariate analysis demonstrated significant differences in 2-year overall survival (OS) (Fav: 67.7%, IM: 64.9% and Adv: 53.9%; p

Published
2021

4. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Al Malki, Monzr, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, Van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, and Weisdorf, Daniel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Blood, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

The authors inadvertently included grant numbers OT3HL147741 & U24CA233032, which are grant-specific. This was an oversight on the authors’ part as these grants did not support the research in this publication.

Published
2021

5. Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis

Author

Murthy, Hemant S., Zhang, Mei-Jie, Chen, Karen, Ahmed, Sairah, Deotare, Uday, Ganguly, Siddhartha, Kansagra, Ankit, Michelis, Fotios V., Nishihori, Taiga, Patnaik, Mrinal, Abid, Muhammad Bilal, Aljurf, Mahmoud, Arai, Yasuyuki, Bacher, Ulrike, Badar, Talha, Badawy, Sherif M., Ballen, Karen, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya Raj, Brown, Valerie I., Martino, Rodrigo, Cahn, Jean-Yves, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Daly, Andrew, Dholaria, Bhagirathbhai, Diaz Perez, Miguel Angel, Freytes, César O., Grunwald, Michael R., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Jamy, Omer, Joseph, Jacinth, Kanakry, Christopher G., Khera, Nandita, Krem, Maxwell M., Kuwatsuka, Yachiyo, Lazarus, Hillard M., Lekakis, Lazaros J., Liu, Hongtao, Modi, Dipenkumar, Munshi, Pashna N., Mussetti, Alberto, Palmisiano, Neil, Patel, Sagar S., Rizzieri, David A., Seo, Sachiko, Shah, Mithun Vinod, Sharma, Akshay, Sohl, Melhm, Solomon, Scott R., Ulrickson, Matthew, Ustun, Celalettin, van der Poel, Marjolein, Verdonck, Leo F., Wagner, John L., Wang, Trent, Wirk, Baldeep, Zeidan, Amer, Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Weisdorf, Daniel J., Saber, Wael, and Kharfan-Dabaja, Mohamed A.

Published
2023
Full Text
View/download PDF

6. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study.

Author

Bejanyan, Nelli, Zhang, Meijie, Bo-Subait, Khalid, Brunstein, Claudio, Wang, Hailin, Warlick, Erica, Giralt, Sergio, Nishihori, Taiga, Martino, Rodrigo, Passweg, Jakob, Dias, Ajoy, Copelan, Edward, Hale, Gregory, Gale, Robert, Solh, Melhem, Kharfan-Dabaja, Mohamed, Diaz, Miguel, Ganguly, Siddhartha, Gore, Steven, Verdonck, Leo, Hossain, Nasheed, Kekre, Natasha, Savani, Bipin, Byrne, Michael, Kanakry, Christopher, Cairo, Mitchell, Ciurea, Stefan, Schouten, Harry, Bredeson, Christopher, Munker, Reinhold, Lazarus, Hillard, Cahn, Jean-Yves, van Der Poel, Marjolein, Rizzieri, David, Yared, Jean, Freytes, Cesar, Cerny, Jan, Aljurf, Mahmoud, Palmisiano, Neil, Pawarode, Attaphol, Bacher, Vera, Grunwald, Michael, Nathan, Sunita, Wirk, Baldeep, Hildebrandt, Gerhard, Seo, Sachiko, Olsson, Richard, George, Biju, de Lima, Marcos, Hourigan, Christopher, Sandmaier, Brenda, Litzow, Mark, Kebriaei, Partow, Saber, Wael, and Weisdorf, Daniel

Subjects
AML, DRI, MDS, Myeloablative, RIC, Adult, Aged, Disease-Free Survival, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Middle Aged, Myelodysplastic Syndromes, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous
Abstract

Compared with reduced-intensity conditioning (RIC), myeloablative conditioning (MAC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, disease-specific risk factors in AML/MDS can further inform when MAC and RIC may yield differential outcomes. We analyzed HCT outcomes stratified by the Disease Risk Index (DRI) in 4387 adults (age 40 to 65 years) to identify the impact of conditioning intensity. In the low/intermediate-risk DRI cohort, RIC was associated with lower nonrelapse mortality (NRM) (hazard ratio [HR], .74; 95% confidence interval [CI], .62 to .88; P < .001) but significantly greater relapse risk (HR, 1.54; 95% CI, 1.35 to 1.76; P < .001) and thus inferior disease-free survival (DFS) (HR, 1.19; 95% CI, 1.07 to 1.33; P = .001). In the high/very high-risk DRI cohort, RIC was associated with marginally lower NRM (HR, .83; 95% CI, .68 to 1.00; P = .051) and significantly higher relapse risk (HR, 1.23; 95% CI, 1.08 to 1.41; P = .002), leading to similar DFS using either RIC or MAC. These data support MAC over RIC as the preferred conditioning intensity for patients with AML/MDS with low/intermediate-risk DRI, but with a similar benefit as RIC in high/very high-risk DRI. Novel MAC regimens with less toxicity could benefit all patients, but more potent antineoplastic approaches are needed for the high/very-high risk DRI group.

Published
2021

9. Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research

Author

Lazaryan, Aleksandr, Dolan, Michelle, Zhang, Mei-Jie, Wang, Hai-Lin, Kharfan-Dabaja, Mohamed A, Marks, David I, Bejanyan, Nelli, Copelan, Edward, Majhail, Navneet S, Waller, Edmund K, Chao, Nelson, Prestidge, Tim, Nishihori, Taiga, Kebriaei, Partow, Inamoto, Yoshihiro, Hamilton, Betty, Hashmi, Shahrukh K, Kamble, Rammurti T, Bacher, Ulrike, Hildebrandt, Gerhard C, Stiff, Patrick J, McGuirk, Joseph, Aldoss, Ibrahim, Beitinjaneh, Amer M, Muffly, Lori, Vij, Ravi, Olsson, Richard F, Byrne, Michael, Schultz, Kirk R, Aljurf, Mahmoud, Seftel, Matthew, Savoie, Mary Lynn, Savani, Bipin N, Verdonck, Leo F, Cairo, Mitchell S, Hossain, Nasheed, Bhatt, Vijaya Raj, Frangoul, Haydar A, Abdel-Azim, Hisham, Malki, Monzr Al, Munker, Reinhold, Rizzieri, David, Khera, Nandita, Nakamura, Ryotaro, Ringdén, Olle, van der Poel, Marjolein, Murthy, Hemant S, Liu, Hongtao, Mori, Shahram, De Oliveira, Satiro, Bolaños-Meade, Javier, Elsawy, Mahmoud, Barba, Pere, Nathan, Sunita, George, Biju, Pawarode, Attaphol, Grunwald, Michael, Agrawal, Vaibhav, Wang, Youjin, Assal, Amer, Caro, Paul Castillo, Kuwatsuka, Yachiyo, Seo, Sachiko, Ustun, Celalettin, Politikos, Ioannis, Lazarus, Hillard M, Saber, Wael, Sandmaier, Brenda M, De Lima, Marcos, Litzow, Mark, Bachanova, Veronika, Weisdorf, Daniel, and Committee of the CIBMTR, Acute Leukemia

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Rare Diseases, Pediatric Cancer, Transplantation, Childhood Leukemia, Hematology, Cancer, Pediatric, Stem Cell Research, Adult, Chromosome Aberrations, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Retrospective Studies, Transplantation Conditioning, Transplantation, Homologous, Acute Leukemia Committee of the CIBMTR, Cardiorespiratory Medicine and Haematology, Immunology, Cardiovascular medicine and haematology
Abstract

Cytogenetic risk stratification at diagnosis has long been one of the most useful tools to assess prognosis in acute lymphoblastic leukemia (ALL). To examine the prognostic impact of cytogenetic abnormalities on outcomes after allogeneic hematopoietic cell transplantation, we studied 1731 adults with Philadelphia-negative ALL in complete remission who underwent myeloablative or reduced intensity/non-myeloablative conditioning transplant from unrelated or matched sibling donors reported to the Center for International Blood and Marrow Transplant Research. A total of 632 patients had abnormal conventional metaphase cytogenetics. The leukemia-free survival and overall survival rates at 5 years after transplantation in patients with abnormal cytogenetics were 40% and 42%, respectively, which were similar to those in patients with a normal karyotype. Of the previously established cytogenetic risk classifications, modified Medical Research Council-Eastern Cooperative Oncology Group score was the only independent prognosticator of leukemia-free survival (P=0.03). In the multivariable analysis, monosomy 7 predicted post-transplant relapse [hazard ratio (HR)=2.11; 95% confidence interval (95% CI): 1.04-4.27] and treatment failure (HR=1.97; 95% CI: 1.20-3.24). Complex karyotype was prognostic for relapse (HR=1.69; 95% CI: 1.06-2.69), whereas t(8;14) predicted treatment failure (HR=2.85; 95% CI: 1.35-6.02) and overall mortality (HR=3.03; 95% CI: 1.44-6.41). This large study suggested a novel transplant-specific cytogenetic scheme with adverse [monosomy 7, complex karyotype, del(7q), t(8;14), t(11;19), del(11q), tetraploidy/near triploidy], intermediate (normal karyotype and all other abnormalities), and favorable (high hyperdiploidy) risks to prognosticate leukemia-free survival (P=0.02). Although some previously established high-risk Philadelphia-negative cytogenetic abnormalities in ALL can be overcome by transplantation, monosomy 7, complex karyotype, and t(8;14) continue to pose significant risks and yield inferior outcomes.

Published
2020

10. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries

Author

Zinter, Matt S, Logan, Brent R, Fretham, Caitrin, Sapru, Anil, Abraham, Allistair, Aljurf, Mahmoud D, Arnold, Staci D, Artz, Andrew, Auletta, Jeffery J, Chhabra, Saurabh, Copelan, Edward, Duncan, Christine, Gale, Robert P, Guinan, Eva, Hematti, Peiman, Keating, Amy K, Marks, David I, Olsson, Richard, Savani, Bipin N, Ustun, Celalettin, Williams, Kirsten M, Pasquini, Marcelo C, and Dvorak, Christopher C

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Patient Safety, Clinical Research, Pediatric, Rare Diseases, Cancer, Hematology, Transplantation, Good Health and Well Being, Child, Critical Illness, Hematopoietic Stem Cell Transplantation, Humans, Infant, Intensive Care Units, Pediatric, Registries, Retrospective Studies, Risk Factors, Intensive care units, Hematopoietic stem cell transplantation, Organ dysfunction scores, Prognosis, Survival analysis, Immunology, Cardiovascular medicine and haematology
Abstract

Critically ill pediatric allogeneic hematopoietic cell transplant (HCT) patients may benefit from early and aggressive interventions aimed at reversing the progression of multiorgan dysfunction. Therefore, we evaluated 25 early risk factors for pediatric intensive care unit (PICU) mortality to improve mortality prognostication. We merged the Virtual Pediatric Systems and Center for International Blood and Marrow Transplant Research databases and analyzed 936 critically ill patients ≤21 years of age who had undergone allogeneic HCT and subsequently required PICU admission between January 1, 2009, and December 31, 2014. Of 1532 PICU admissions, the overall PICU mortality rate was 17.4% (95% confidence interval [CI], 15.6% to 19.4%) but was significantly higher for patients requiring mechanical ventilation (44.0%), renal replacement therapy (56.1%), or extracorporeal life support (77.8%). Mortality estimates increased significantly the longer that patients remained in the PICU. Of 25 HCT- and PICU-specific characteristics available at or near the time of PICU admission, moderate/severe pre-HCT renal injury, pre-HCT recipient cytomegalovirus seropositivity,

Published
2020

11. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.

Author

Rashidi, Armin, Hamadani, Mehdi, Zhang, Mei-Jie, Wang, Hai-Lin, Abdel-Azim, Hisham, Aljurf, Mahmoud, Assal, Amer, Bajel, Ashish, Bashey, Asad, Battiwalla, Minoo, Beitinjaneh, Amer, Bejanyan, Nelli, Bhatt, Vijaya, Bolaños-Meade, Javier, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Ciurea, Stefan, Copelan, Edward, Cutler, Corey, Daly, Andrew, Diaz, Miguel-Angel, Farhadfar, Nosha, Gale, Robert, Ganguly, Siddhartha, Grunwald, Michael, Hahn, Theresa, Hashmi, Shahrukh, Hildebrandt, Gerhard, Holland, H, Hossain, Nasheed, Kanakry, Christopher, Kharfan-Dabaja, Mohamed, Khera, Nandita, Koc, Yener, Lazarus, Hillard, Lee, Jong-Wook, Maertens, Johan, Martino, Rodrigo, McGuirk, Joseph, Munker, Reinhold, Murthy, Hemant, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Palmisiano, Neil, Patel, Sagar, Pidala, Joseph, Olin, Rebecca, Olsson, Richard, Oran, Betul, Ringden, Olov, Rizzieri, David, Rowe, Jacob, Savoie, Mary, Schultz, Kirk, Seo, Sachiko, Shaffer, Brian, Singh, Anurag, Solh, Melhem, Stockerl-Goldstein, Keith, Verdonck, Leo, Wagner, John, Waller, Edmund, De Lima, Marcos, Sandmaier, Brenda, Litzow, Mark, Weisdorf, Dan, Romee, Rizwan, and Saber, Wael

Subjects
Adolescent, Adult, Aged, Blood Donors, Bone Marrow Transplantation, Calcineurin Inhibitors, Chronic Disease, Cyclophosphamide, Disease-Free Survival, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Immunosuppressive Agents, Incidence, Leukemia, Myeloid, Acute, Male, Middle Aged, Recurrence, Remission Induction, Retrospective Studies, Siblings, Survival Analysis, Transplantation Conditioning, Transplantation, Haploidentical, Young Adult
Abstract

HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy-based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease-donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy-based Haplo-HCT vs MSD using calcineurin inhibitor-based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.

Published
2019

12. Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation

Author

Bejanyan, Nelli, Zhang, Mei-Jie, Wang, Hai-Lin, Lazaryan, Aleksandr, de Lima, Marcos, Marks, David I, Sandmaier, Brenda M, Bachanova, Veronika, Rowe, Jacob, Tallman, Martin, Kebriaei, Partow, Kharfan-Dabaja, Mohamed, Gale, Robert Peter, Lazarus, Hillard M, Ustun, Celalettin, Copelan, Edward, Hamilton, Betty Ky, Schiller, Gary, Hogan, William, Hashmi, Shahrukh, Seftel, Matthew, Kanakry, Christopher G, Olsson, Richard F, Martino, Rodrigo, Saber, Wael, Khoury, H Jean, and Weisdorf, Daniel J

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Clinical Research, Rare Diseases, Stem Cell Research - Nonembryonic - Human, Hematology, Cancer, Transplantation, Clinical Trials and Supportive Activities, Stem Cell Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Adult, Aged, Consolidation Chemotherapy, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Middle Aged, Myeloablative Agonists, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Recurrence, Survival Analysis, Time Factors, Transplantation, Homologous, Treatment Outcome, Young Adult, ALL, Consolidation chemotherapy, Myeloablative.conditioning, Allogeneic transplant, Myeloablative conditioning, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received ≥2 (n = 109), 1 (n = 93), or 0 cycles (n = 322) of consolidation before myeloablative alloHCT from 2008 to 2012. As expected, time to alloHCT was longer with increasing cycles of consolidation. Patients receiving ≥2, 1, or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20%, 27%, and 22%; 1-year transplant-related mortality (TRM) of 16%, 18%, and 23%; adjusted 3-year leukemia-free survival (LFS) of 54%, 48%, and 47%; and 3-year overall survival (OS) of 63%, 59%, and 54% (all P values >.40). Multivariable analysis confirmed that consolidation was not prognostic for LFS (relative risk, 1.20, 95% confidence interval, .86 to 1.67; P = .28 for no consolidation; RR, 1.18, 95% confidence interval, .79 to 1.76; P = .41 for 1 cycle versus ≥2 cycles = reference). Similarly, consolidation was not associated with OS, relapse, TRM, or graft-versus-host disease. We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.

Published
2018

13. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors

Author

Grunwald, Michael R., Zhang, Mei-Jie, Elmariah, Hany, Johnson, Mariam H., St. Martin, Andrew, Bashey, Asad, Battiwalla, Minoo, Bredeson, Christopher N., Copelan, Edward, Cutler, Corey S., George, Biju R., Gupta, Vikas, Kanakry, Christopher, Mehta, Rohtesh S., Milano, Filippo, Mussetti, Alberto, Nakamura, Ryotaro, Nishihori, Taiga, Saber, Wael, Solh, Melhem, Weisdorf, Daniel J., and Eapen, Mary

Published
2021
Full Text
View/download PDF

14. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes

Author

Nazha, Aziz, Hu, Zhen-Huan, Wang, Tao, Lindsley, R. Coleman, Abdel-Azim, Hisham, Aljurf, Mahmoud, Bacher, Ulrike, Bashey, Asad, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, DeFilipp, Zachariah, Diaz, Miguel Angel, Farhadfar, Nosha, Gadalla, Shahinaz M., Gale, Robert Peter, George, Biju, Gergis, Usama, Grunwald, Michael R., Hamilton, Betty, Hashmi, Shahrukh, Hildebrandt, Gerhard C., Inamoto, Yoshihiro, Kalaycio, Matt, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed A., Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Majhail, Navneet S., Murthy, Hemant S., Nathan, Sunita, Nishihori, Taiga, Pawarode, Attaphol, Rizzieri, David, Sabloff, Mitchell, Savani, Bipin N., Schachter, Levanto, Schouten, Harry C., Seo, Sachiko, Shah, Nirav N., Solh, Melhem, Valcárcel, David, Vij, Ravi, Warlick, Erica, Wirk, Baldeep, Wood, William A., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald M., Scott, Bart L., Nakamura, Ryotaro, and Saber, Wael

Published
2020
Full Text
View/download PDF

15. Comparison of outcomes of HCT in blast phase of BCR-ABL1− MPN with de novo AML and with AML following MDS

Author

Gupta, Vikas, Kim, Soyoung, Hu, Zhen-Huan, Liu, Ying, Aljurf, Mahmoud, Bacher, Ulrike, Beitinjaneh, Amer, Cahn, Jean-Yves, Cerny, Jan, Copelan, Edward, Gadalla, Shahinaz M., Gale, Robert Peter, Ganguly, Siddhartha, George, Biju, Gerds, Aaron T., Gergis, Usama, Hamilton, Betty K., Hashmi, Shahrukh, Hildebrandt, Gerhard C., Kamble, Rammurti T., Kindwall-Keller, Tamila, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Maziarz, Richard T., Nishihori, Taiga, Olsson, Richard F., Rizzieri, David, Savani, Bipin N., Seo, Sachiko, Solh, Melhem, Szer, Jeff, Verdonck, Leo F., Wirk, Baldeep, Woolfrey, Ann, Yared, Jean A., Alyea, Edwin P., Popat, Uday R., Sobecks, Ronald M., Scott, Bart L., Nakamura, Ryotaro, and Saber, Wael

Published
2020
Full Text
View/download PDF

16. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report

Author

Zhou, Zheng, Nath, Rajneesh, Cerny, Jan, Wang, Hai-Lin, Zhang, Mei-Jie, Abdel-Azim, Hisham, Agrawal, Vaibhav, Ahmed, Gulrayz, Al-Homsi, A. Samer, Aljurf, Mahmoud, Alkhateeb, Hassan B., Assal, Amer, Bacher, Ulrike, Bajel, Ashish, Bashir, Qaiser, Battiwalla, Minocher, Bhatt, Vijaya Raj, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Choe, Hannah, Copelan, Edward, Cutler, Corey, Damlaj, Moussab B., DeFilipp, Zachariah, De Lima, Marcos, Diaz, Miguel Angel, Farhadfar, Nosha, Foran, James, Freytes, César O., Gerds, Aaron T., Gergis, Usama, Grunwald, Michael R., Gul, Zartash, Hamadani, Mehdi, Hashmi, Shahrukh, Hertzberg, Mark, Hildebrandt, Gerhard C., Hossain, Nasheed, Inamoto, Yoshihiro, Isola, Luis, Jain, Tania, Kamble, Rammurti T., Khan, Muhammad Waqas, Kharfan-Dabaja, Mohamed A., Kebriaei, Partow, Kekre, Natasha, Khera, Nandita, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark, Liu, Hongtao, Marks, David I., Martino, Rodrigo, Mathews, Vikram, Mishra, Asmita, Murthy, Hemant S., Nagler, Arnon, Nakamura, Ryotaro, Nathan, Sunita, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Palmisiano, Neil, Patel, Sagar S., Patnaik, Mrinal M., Pawarode, Attaphol, Perales, Miguel-Angel, Politikos, Ioannis, Popat, Uday, Rizzieri, David, Sandmaier, Brenda M., Savani, Bipin N., Seo, Sachiko, Shah, Nirav N., Uy, Geoffrey L., Valcárcel, David, Verdonck, Leo F., Waller, Edmund K., Wang, Youjin, Weisdorf, Daniel, Wirk, Baldeep, Wong, Eric, Yared, Jean A., and Saber, Wael

Published
2020
Full Text
View/download PDF

17. Subsequent neoplasms and late mortality in children undergoing allogeneic transplantation for nonmalignant diseases

Author

Kahn, Justine M., Brazauskas, Ruta, Tecca, Heather R., Bo-Subait, Stephanie, Buchbinder, David, Battiwala, Minoo, Flowers, Mary E.D., Savani, Bipin N., Phelan, Rachel, Broglie, Larisa, Abraham, Allistair A., Keating, Amy K., Daly, Andrew, Wirk, Baldeep, George, Biju, Alter, Blanche P., Ustun, Celalettin, Freytes, Cesar O., Beitinjaneh, Amer M., Duncan, Christine, Copelan, Edward, Hildebrandt, Gerhard C., Murthy, Hemant S., Lazarus, Hillard M., Auletta, Jeffery J., Myers, Kasiani C., Williams, Kirsten M., Page, Kristin M., Vrooman, Lynda M., Norkin, Maxim, Byrne, Michael, Diaz, Miguel Angel, Kamani, Naynesh, Bhatt, Neel S., Rezvani, Andrew, Farhadfar, Nosha, Mehta, Parinda A., Hematti, Peiman, Shaw, Peter J., Kamble, Rammurti T., Schears, Raquel, Olsson, Richard F., Hayashi, Robert J., Gale, Robert Peter, Mayo, Samantha J., Chhabra, Saurabh, Rotz, Seth J., Badawy, Sherif M., Ganguly, Siddhartha, Pavletic, Steven, Nishihori, Taiga, Prestidge, Tim, Agrawal, Vaibhav, Hogan, William J., Inamoto, Yoshihiro, Shaw, Bronwen E., and Satwani, Prakash

Published
2020
Full Text
View/download PDF

18. Survival following allogeneic transplant in patients with myelofibrosis

Author

Gowin, Krisstina, Ballen, Karen, Ahn, Kwang Woo, Hu, Zhen-Huan, Ali, Haris, Arcasoy, Murat O., Devlin, Rebecca, Coakley, Maria, Gerds, Aaron T., Green, Michael, Gupta, Vikas, Hobbs, Gabriela, Jain, Tania, Kandarpa, Malathi, Komrokji, Rami, Kuykendall, Andrew T., Luber, Kierstin, Masarova, Lucia, Michaelis, Laura C., Patches, Sarah, Pariser, Ashley C., Rampal, Raajit, Stein, Brady, Talpaz, Moshe, Verstovsek, Srdan, Wadleigh, Martha, Agrawal, Vaibhav, Aljurf, Mahmoud, Angel Diaz, Miguel, Avalos, Belinda R., Bacher, Ulrike, Bashey, Asad, Beitinjaneh, Amer M., Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey S., DeFilipp, Zachariah, Gadalla, Shahinaz M., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh K., Kharfan-Dabaja, Mohamed A., Kindwall-Keller, Tamila, Kröger, Nicolaus, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Rowe, Jacob M., Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Tamari, Roni, Verdonck, Leo F., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Nakamura, Ryotaro, Mesa, Ruben, and Saber, Wael

Published
2020
Full Text
View/download PDF

19. Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries

Author

Zinter, Matt S., Logan, Brent R., Fretham, Caitrin, Sapru, Anil, Abraham, Allistair, Aljurf, Mahmoud D., Arnold, Staci D., Artz, Andrew, Auletta, Jeffery J., Chhabra, Saurabh, Copelan, Edward, Duncan, Christine, Gale, Robert P., Guinan, Eva, Hematti, Peiman, Keating, Amy K., Marks, David I., Olsson, Richard, Savani, Bipin N., Ustun, Celalettin, Williams, Kirsten M., Pasquini, Marcelo C., and Dvorak, Christopher C.

Published
2020
Full Text
View/download PDF

22. Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades

Author

Kilari, Deepak, D'Souza, Anita, Fraser, Raphael, Qayed, Muna, Davila, Omar, Agrawal, Vaibhav, Diaz, Miguel Angel, Chhabra, Saurabh, Cerny, Jan, Copelan, Edward, Farhadfar, Nosha, Freytes, Cesar O., Gale, Robert Peter, Ganguly, Siddhartha, Hildebrandt, Gerhard C., Holmberg, Leona, Kamble, Rammurti T., Kapoor, Prashant, Lazarus, Hillard, Lee, Cindy, Murthy, Hemant S., Naik, Seema, Nishihori, Taiga, Saad, Ayman, Savani, Bipin N., Seo, Sachiko, Warwick, Anne, Wirk, Baldeep, Yared, Jean A., Nieto, Yago, and Hari, Parameswaran

Published
2019
Full Text
View/download PDF

23. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis

Author

Casulo, Carla, Friedberg, Jonathan W., Ahn, Kwang W., Flowers, Christopher, DiGilio, Alyssa, Smith, Sonali M., Ahmed, Sairah, Inwards, David, Aljurf, Mahmoud, Chen, Andy I., Choe, Hannah, Cohen, Jonathon, Copelan, Edward, Farooq, Umar, Fenske, Timothy S., Freytes, Cesar, Gaballa, Sameh, Ganguly, Siddhartha, Jethava, Yogesh, Kamble, Rammurti T., Kenkre, Vaishalee P., Lazarus, Hillard, Lazaryan, Aleksandr, Olsson, Richard F., Rezvani, Andrew R., Rizzieri, David, Seo, Sachiko, Shah, Gunjan L., Shah, Nina, Solh, Melham, Sureda, Anna, William, Basem, Cumpston, Aaron, Zelenetz, Andrew D., Link, Brian K., and Hamadani, Mehdi

Published
2018
Full Text
View/download PDF

24. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia

Author

Hogan, William, Battiwalla, Minoo, Copelan, Edward, Hildebrandt, Gerhard, Ganguly, Sid, Majhail, Navneet, Woolfrey, Ann, Nivison-Smith, Ian, Hertzberg, Mark, Diaz, Miguel Angel, Jakubowski, Ann, Ustun, Celalettin, Yong, Agnes, Freytes, Cesar, DeFilipp, Zachariah, Inamoto, Yoshi, Cahn, Jean-Yves, Savani, Bipin, Yared, Jean, Bajel, Ashish, Bacher, Ulrike, Uy, Geoffrey, Rizzieri, David, Wieduwilt, Matthew, Schultz, Kirk, Grunwald, Michael, Kamble, Rammurti, Qayed, Muna, Brammer, Jonathan, Ballen, Karen, Khera, Nandita, Schouten, Harry, Bierings, Marc, Kanakry, Christopher, Wood, William Allen, Saad, Ayman, Savoie, Lynn, Hamilton, Betty Ky, Aljurf, Mahmoud, Vij, Ravi, Pawarode, Attaphol, Olsson, Richard, Wirk, B. Mona, Beitinjaneh, Amer, Seo, Sachiko, Cerny, Jan, Akpek, Gorgun, Norkin, Maxim, Nishihori, Taiga, Lazaryan, Aleksandr, Sabloff, Mitchell, Kebriaei, Partow, Anasetti, Claudio, Zhang, Mei-Jie, Wang, Hai-Lin, Aldoss, Ibrahim, de Lima, Marcos, Khoury, H. Jean, Sandmaier, Brenda M., Horowitz, Mary M., Artz, Andrew, Bejanyan, Nelli, Ciurea, Stefan, Lazarus, Hillard M., Gale, Robert Peter, Litzow, Mark, Bredeson, Christopher, Seftel, Matthew D., Pulsipher, Michael A., Boelens, Jaap-Jan, Alvarnas, Joseph, Champlin, Richard, Forman, Stephen, Pullarkat, Vinod, Weisdorf, Daniel, and Marks, David I.

Published
2018
Full Text
View/download PDF

25. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival

Author

Htut, Myo, D'Souza, Anita, Krishnan, Amrita, Bruno, Benedetto, Zhang, Mei-Jie, Fei, Mingwei, Diaz, Miguel Angel, Copelan, Edward, Ganguly, Siddhartha, Hamadani, Mehdi, Kharfan-Dabaja, Mohamed, Lazarus, Hillard, Lee, Cindy, Meehan, Kenneth, Nishihori, Taiga, Saad, Ayman, Seo, Sachiko, Ramanathan, Muthalagu, Usmani, Saad Z., Gasparetto, Christina, Mark, Tomer M., Nieto, Yago, and Hari, Parameswaran

Published
2018
Full Text
View/download PDF

26. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Author

Muffly, Lori, Pasquini, Marcelo C., Martens, Michael, Brazauskas, Ruta, Zhu, Xiaochun, Adekola, Kehinde, Aljurf, Mahmoud, Ballen, Karen K., Bajel, Ashish, Baron, Frederic, Battiwalla, Minoo, Beitinjaneh, Amer, Cahn, Jean-Yves, Carabasi, Mathew, Chen, Yi-Bin, Chhabra, Saurabh, Ciurea, Stefan, Copelan, Edward, D'Souza, Anita, Edwards, John, Foran, James, Freytes, Cesar O., Fung, Henry C., Gale, Robert Peter, Giralt, Sergio, Hashmi, Shahrukh K., Hildebrandt, Gerhard C., Ho, Vincent, Jakubowski, Ann, Lazarus, Hillard, Luskin, Marlise R., Martino, Rodrigo, Maziarz, Richard, McCarthy, Philip, Nishihori, Taiga, Olin, Rebecca, Olsson, Richard F., Pawarode, Attaphol, Peres, Edward, Rezvani, Andrew R., Rizzieri, David, Savani, Bipin N., Schouten, Harry C., Sabloff, Mitchell, Seftel, Matthew, Seo, Sachiko, Sorror, Mohamed L., Szer, Jeff, Wirk, Baldeep M., Wood, William A., and Artz, Andrew

Published
2017
Full Text
View/download PDF

27. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes

Author

Oran, Betül, Ahn, Kwang Woo, Fretham, Caitrin, Beitinjaneh, Amer, Bashey, Asad, Pawarode, Attaphol, Wirk, Baldeep, Scott, Bart L., Savani, Bipin N., Bredeson, Christopher, Weisdorf, Daniel, Marks, David I., Rizzieri, David, Copelan, Edward, Hildebrandt, Gerhard C., Hale, Gregory A., Murthy, Hemant S., Lazarus, Hillard M., Cerny, Jan, Liesveld, Jane L., Yared, Jean A., Yves-Cahn, Jean, Szer, Jeffrey, Verdonck, Leo F., Aljurf, Mahmoud, van der Poel, Marjolein, Litzow, Mark, Kalaycio, Matt, Grunwald, Michael R., Diaz, Miguel Angel, Sabloff, Mitchell, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Farhadfar, Nosha, Reshef, Ran, Olsson, Richard F., Gale, Robert Peter, Nakamura, Ryotaro, Seo, Sachiko, Chhabra, Saurabh, Hashmi, Shahrukh, Farhan, Shatha, Ganguly, Siddhartha, Nathan, Sunita, Nishihori, Taiga, Jain, Tania, Agrawal, Vaibhav, Bacher, Ulrike, Popat, Uday, and Saber, Wael

Published
2021
Full Text
View/download PDF

28. Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia

Author

Liu, Hien Duong, Ahn, Kwang Woo, Hu, Zhen-Huan, Hamadani, Mehdi, Nishihori, Taiga, Wirk, Baldeep, Beitinjaneh, Amer, Rizzieri, David, Grunwald, Michael R., Sabloff, Mitchell, Olsson, Richard F., Bajel, Ashish, Bredeson, Christopher, Daly, Andrew, Inamoto, Yoshihiro, Majhail, Navneet, Saad, Ayman, Gupta, Vikas, Gerds, Aaron, Malone, Adriana, Tallman, Martin, Reshef, Ran, Marks, David I., Copelan, Edward, Gergis, Usama, Savoie, Mary Lynn, Ustun, Celalettin, Litzow, Mark R., Cahn, Jean-Yves, Kindwall-Keller, Tamila, Akpek, Gorgun, Savani, Bipin N., Aljurf, Mahmoud, Rowe, Jacob M., Wiernik, Peter H., Hsu, Jack W., Cortes, Jorge, Kalaycio, Matt, Maziarz, Richard, Sobecks, Ronald, Popat, Uday, Alyea, Edwin, and Saber, Wael

Published
2017
Full Text
View/download PDF

29. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma

Author

Cornell, Robert F., Bachanova, Veronika, D'Souza, Anita, Woo-Ahn, Kwang, Martens, Michael, Huang, Jiaxing, Al-Homsi, A. Samer, Chhabra, Saurabh, Copelan, Edward, Diaz, Miguel-Angel, Freytes, Cesar O., Gale, Robert Peter, Ganguly, Siddhartha, Hamadani, Mehdi, Hildebrandt, Gerhard, Kamble, Rammurti T., Kharfan-Dabaja, Mohamed, Kindwall-Keller, Tamila, Lazarus, Hillard M., Marks, David I., Nishihori, Taiga, Olsson, Richard F., Saad, Ayman, Usmani, Saad, Vesole, David H., Yared, Jean, Mark, Tomer, Nieto, Yago, and Hari, Parameswaran

Published
2017
Full Text
View/download PDF

30. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies

Author

Pasquini, Marcelo C., Zhang, Mei-Jie, Medeiros, Bruno C., Armand, Philippe, Hu, Zhen-Huan, Nishihori, Taiga, Aljurf, Mahmoud D., Akpek, Görgün, Cahn, Jean-Yves, Cairo, Mitchell S., Cerny, Jan, Copelan, Edward A., Deol, Abhinav, Freytes, César O., Gale, Robert Peter, Ganguly, Siddhartha, George, Biju, Gupta, Vikas, Hale, Gregory A., Kamble, Rammurti T., Klumpp, Thomas R., Lazarus, Hillard M., Luger, Selina M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Martino, Rodrigo, Norkin, Maxim, Olsson, Richard F., Oran, Betul, Pawarode, Attaphol, Pulsipher, Michael A., Ramanathan, Muthalagu, Reshef, Ran, Saad, Ayman A., Saber, Wael, Savani, Bipin N., Schouten, Harry C., Ringdén, Olle, Tallman, Martin S., Uy, Geoffrey L., Wood, William A., Jr., Wirk, Baldeep, Pérez, Waleska S., Batiwalla, Minoo, and Weisdorf, Daniel J.

Published
2016
Full Text
View/download PDF

33. Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation

Author

Copelan, Edward A., Avalos, Belinda R., Ahn, Kwang Woo, Zhu, Xiaochun, Gale, Robert Peter, Grunwald, Michael R., Hamadani, Mehdi, Hamilton, Betty K., Hale, Gregory A., Marks, David I., Waller, Edmund K., Savani, Bipin N., Costa, Luciano J., Ramanathan, Muthalagu, Cahn, Jean-Yves, Khoury, H. Jean, Weisdorf, Daniel J., Inamoto, Yoshihiro, Kamble, Rammurti T., Schouten, Harry C., Wirk, Baldeep, Litzow, Mark R., Aljurf, Mahmoud D., van Besien, Koen W., Ustun, Celalettin, Bolwell, Brian J., Bredeson, Christopher N., Fasan, Omotayo, Ghosh, Nilanjan, Horowitz, Mary M., Arora, Mukta, Szer, Jeffrey, Loren, Alison W., Alyea, Edwin P., Cortes, Jorge, Maziarz, Richard T., Kalaycio, Matt E., and Saber, Wael

Published
2015
Full Text
View/download PDF

35. Impact of Race, Ethnicity, and Social Determinants of Heath on Outcomes for Acute Myeloid Leukemia Patients in a System with Specialized Nurse Navigation

Author

Ragon, Brittany Knick, primary, Boselli, Danielle, additional, Bose, Rupali, additional, Begley, Stephanie, additional, Aguiar, Melissa, additional, Blackley, Kris, additional, Shah, Nilay A., additional, Chojecki, Aleksander L., additional, Sanikommu, Srinivasa Reddy R., additional, Ai, Jing, additional, Druhan, Lawrence J, additional, Steuerwald, Nury M, additional, Patel, Jai N, additional, Symanowski, James T., additional, Avalos, Belinda R., additional, Copelan, Edward A., additional, Raghavan, Derek, additional, Knight, Thomas G., additional, and Grunwald, Michael R., additional

Published
2022
Full Text
View/download PDF

36. Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia

Author

Knight, Thomas G., primary, Symanowski, James T., additional, Ai, Jing, additional, Ragon, Brittany Knick, additional, Chojecki, Aleksander L., additional, Shah, Nilay A., additional, Sanikommu, Srinivasa Reddy, additional, Copelan, Edward A., additional, Walsh, Declan, additional, Grunwald, Michael R., additional, and Meadors, Patrick L, additional

Published
2022
Full Text
View/download PDF

37. Factors Predicting Efficacy and Toxicity of Post Transplantation Cyclophosphamide for Graft Versus Host Disease Prevention in Hematopoietic Cell Transplantation Recipients: Interim Data of an Ongoing Study

Author

Chojecki, Aleksander L., primary, Patel, Jai N., additional, Foureau, David M, additional, Symanowski, James, additional, Begic, Xhevahire, additional, Davis, Michael, additional, Steuerwald, Nury M, additional, Norek, Sarah, additional, Sanikommu, Srinivasa Reddy R., additional, Shah, Nilay A., additional, Ragon, Brittany Knick, additional, Knight, Thomas G., additional, Ai, Jing, additional, Grunwald, Michael R., additional, Ghosh, Nilanjan, additional, Druhan, Lawrence J, additional, Avalos, Belinda R., additional, and Copelan, Edward A., additional

Published
2022
Full Text
View/download PDF

38. Clonal Hematopoiesis Prevalence and Mutational Spectrum in Patients with Plasma Cell Disorders at the Time of Diagnosis and Its Impact on Clinical Features, Cardiovascular Complications, and Survival

Author

Sanikommu, Srinivasa Reddy, primary, Atrash, Shebli, additional, Robinson, Myra, additional, Steuerwald, Nury M., additional, Cassetta, Kristen, additional, Yang, Hsih-Te, additional, Usmani, Saad, additional, Copelan, Edward A., additional, Avalos, Belinda R., additional, and Druhan, Lawrence J., additional

Published
2022
Full Text
View/download PDF

40. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

Author

Copelan, Edward A., Hamilton, Betty K., Avalos, Belinda, Ahn, Kwang Woo, Bolwell, Brian J., Zhu, Xiaochun, Aljurf, Mahmoud, van Besien, Koen, Bredeson, Christopher, Cahn, Jean-Yves, Costa, Luciano J., de Lima, Marcos, Gale, Robert Peter, Hale, Gregory A., Halter, Joerg, Hamadani, Mehdi, Inamoto, Yoshihiro, Kamble, Rammurti T., Litzow, Mark R., Loren, Alison W., Marks, David I., Olavarria, Eduardo, Roy, Vivek, Sabloff, Mitchell, Savani, Bipin N., Seftel, Matthew, Schouten, Harry C., Ustun, Celalettin, Waller, Edmund K., Weisdorf, Daniel J., Wirk, Baldeep, Horowitz, Mary M., Arora, Mukta, Szer, Jeff, Cortes, Jorge, Kalaycio, Matt E., Maziarz, Richard T., and Saber, Wael

Published
2013
Full Text
View/download PDF

41. Providing Personalized Prognostic Information for Adult Leukemia Survivors

Author

Lee, Stephanie J., Storer, Barry, Wang, Hailin, Lazarus, Hillard M., Waller, Edmund K., Isola, Luis M., Klumpp, Thomas R., Umejiego, John Bosco C., Savani, Bipin N., Loren, Alison W., Cairo, Mitchell S., Camitta, Bruce M., Cutler, Corey S., George, Biju, Jean Khoury, H., Marks, David I., Rizzieri, David A., Copelan, Edward A., Gupta, Vikas, Liesveld, Jane L., Litzow, Mark R., Miller, Alan M., Schouten, Harry C., Gale, Robert Peter, Cahn, Jean-Yves, and Weisdorf, Daniel J.

Published
2013
Full Text
View/download PDF

42. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis

Author

Mei, Matthew, primary, Pillai, Raju, additional, Kim, Soyoung, additional, Estrada-Merly, Noel, additional, Afkhami, Michelle, additional, Yang, Lixin, additional, Meng, Zhuo, additional, Abid, Muhammad Bilal, additional, Aljurf, Mahmoud, additional, Bacher, Ulrike, additional, Beitinjaneh, Amer, additional, Bredeson, Christopher, additional, Cahn, Jean-Yves, additional, Cerny, Jan, additional, Copelan, Edward, additional, Cutler, Corey, additional, DeFilipp, Zachariah, additional, Diaz Perez, Miguel Angel, additional, Farhadfar, Nosha, additional, Freytes, César O., additional, Gadalla, Shahinaz M., additional, Ganguly, Siddhartha, additional, Gale, Robert Peter, additional, Gergis, Usama, additional, Grunwald, Michael R., additional, Hamilton, Betty K., additional, Hashmi, Shahrukh, additional, Hildebrandt, Gerhard C., additional, Lazarus, Hillard M., additional, Litzow, Mark, additional, Munker, Reinhold, additional, Murthy, Hemant S., additional, Nathan, Sunita, additional, Nishihori, Taiga, additional, Patel, Sagar S., additional, Rizzieri, David, additional, Seo, Sachiko, additional, Shah, Mithun Vinod, additional, Solh, Melhem, additional, Verdonck, Leo F., additional, Vij, Ravi, additional, Sobecks, Ronald M., additional, Oran, Betul, additional, Scott, Bart L., additional, Saber, Wael, additional, and Nakamura, Ryotaro, additional

Published
2022
Full Text
View/download PDF

43. Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research

Author

Foran, James M., Pavletic, Steven Z., Logan, Brent R., Agovi-Johnson, Manza A., Pérez, Waleska S., Bolwell, Brian J., Bornhäuser, Martin, Bredeson, Christopher N., Cairo, Mitchell S., Camitta, Bruce M., Copelan, Edward A., Dehn, Jason, Gale, Robert P., George, Biju, Gupta, Vikas, Hale, Gregory A., Lazarus, Hillard M., Litzow, Mark R., Maharaj, Dipnarine, Marks, David I., Martino, Rodrigo, Maziarz, Richard T., Rowe, Jacob M., Rowlings, Philip A., Savani, Bipin N., Savoie, Mary Lynn, Szer, Jeffrey, Waller, Edmund K., Wiernik, Peter H., and Weisdorf, Daniel J.

Published
2013
Full Text
View/download PDF

44. Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome

Author

Lukenbill, Joshua, Rybicki, Lisa, Sekeres, Mikkael A., Zaman, Muhammad Omer, Copelan, Alexander, Haddad, Housam, Fraser, Thomas, DiGiorgio, Megan J., Hanna, Rabi, Duong, Hien, Hill, Brian, Kalaycio, Matt, Sobecks, Ronald, Bolwell, Brian, and Copelan, Edward

Published
2013
Full Text
View/download PDF

45. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes

Author

Visconte, Valeria, Rogers, Heesun J., Singh, Jarnail, Barnard, John, Bupathi, Manoj, Traina, Fabiola, McMahon, James, Makishima, Hideki, Szpurka, Hadrian, Jankowska, Anna, Jerez, Andres, Sekeres, Mikkael A., Saunthararajah, Yogen, Advani, Anjali S., Copelan, Edward, Koseki, Haruhiko, Isono, Kyoichi, Padgett, Richard A., Osman, Sami, Koide, Kazunori, O'Keefe, Christine, Maciejewski, Jaroslaw P., and Tiu, Ramon V.

Published
2012
Full Text
View/download PDF

46. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes

Author

Saunthararajah, Yogen, Sekeres, Mikkael, Advani, Anjali, Mahfouz, Reda, Durkin, Lisa, Radivoyevitch, Tomas, Englehaupt, Ricki, Juersivich, Joy, Cooper, Kathleen, Husseinzadeh, Holleh, Przychodzen, Bartlomiej, Rump, Matthew, Hobson, Sean, Earl, Marc, Sobecks, Ronald, Dean, Robert, Reu, Frederic, Tiu, Ramon, Hamilton, Betty, Copelan, Edward, Lichtin, Alan, Hsi, Eric, Kalaycio, Matt, and Maciejewski, Jaroslaw

Subjects
Oncology, Experimental, Myelodysplastic syndromes -- Care and treatment, Apoptosis -- Analysis -- Research, Cancer -- Research, Health care industry
Abstract

BACKGROUND. Mutational inactivation in cancer of key apoptotic pathway components, such as TP53/p53, undermines cytotoxic therapies that aim to increase apoptosis. Accordingly, TP53 mutations are reproducibly associated with poor treatment outcomes. Moreover, cytotoxic treatments destroy normal stem cells with intact p53 systems, a problem especially for myeloid neoplasms, as these cells reverse the low blood counts that cause morbidity and death. Preclinical studies suggest that noncytotoxic concentrations of the DNA methyltransferase 1 (DNMT1) inhibitor decitabine produce p53-independent cellcycle exits by reversing aberrant epigenetic repression of proliferation-terminating (MYC-antagonizing) differentiation genes in cancer cells. METHODS. In this clinical trial, patients with myelodysplastic syndrome (n = 25) received reduced decitabine dosages (0.1-0.2 mg/kg/day compared with the FDA-approved 20-45 mg/[m.sup.2]/day dosage, a 75%-90% reduction) to avoid cytotoxicity. These well-tolerated doses were frequently administered 1-3 days per week, instead of pulse cycled for 3 to 5 days over a 4- to 6-week period, to increase the probability that cancer S-phase entries would coincide with drug exposure, which is required for S-phase-dependent DNMT1 depletion. RESULTS. The median subject age was 73 years (range, 46-85 years), 9 subjects had relapsed disease or were refractory to 5-azacytidine and/or lenalidomide, and 3 had received intensive chemoradiation to treat other cancers. Adverse events were related to neutropenia present at baseline: neutropenic fever (13 of 25 subjects) and septic death (1 of 25 subjects). Blood count improvements meeting the International Working Group criteria for response occurred in 11 of 25 (44%) subjects and were highly durable. Treatment-induced freedom from transfusion lasted a median of 1,025 days (range, 186-1,152 days; 3 ongoing), and 20% of subjects were treated for more than 3 years. Mutations and/or deletions of key apoptosis genes were frequent (present in 55% of responders and in 36% of nonresponders). Noncytotoxic DNMT1 depletion was confirmed by serial BM γ-H2AX (DNA repair/damage marker) and DNMT1 analyses. MYC master oncoprotein levels were markedly decreased. CONCLUSION. Decitabine regimens can be redesigned to minimize cytotoxicity and increase exposure time for DNMT1 depletion, to safely and effectively circumvent mutational apoptotic defects. TRIAL REGISTRATION. Clinicaltrials.gov NCT01165996. FUNDING. NIH (R01CA138858, CA043703); Department of Defense (PR081404); Clinical and Translational Science Award (CTSA) (UL1RR024989); and the Leukemia and Lymphoma Society (Translational Research Program)., Introduction Although conventional cytotoxic treatments for myeloid cancers can have differing proximal actions, e.g., topoisomerase inhibition (daunorubicin) or termination of DNA chain synthesis (cytarabine), a final common pathway converges onto [...]

Published
2015
Full Text
View/download PDF

49. Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission

Author

Farag, Sherif S., Maharry, Kati, Zhang, Mei-Jie, Pérez, Waleska S., George, Stephen L., Mrózek, Krzysztof, DiPersio, John, Bunjes, Donald W., Marcucci, Guido, Baer, Maria R., Cairo, Mitchell, Copelan, Edward, Cutler, Corey S., Isola, Luis, Lazarus, Hillard M., Litzow, Mark R., Marks, David I., Ringdén, Olle, Rizzieri, David A., Soiffer, Robert, Larson, Richard A., Tallman, Martin S., Bloomfield, Clara D., and Weisdorf, Daniel J.

Published
2011
Full Text
View/download PDF

50. Clinical Characteristics and Outcomes of AML Patients Treated with Frontline CPX 351 or HMA/Venetoclax: A Single Institution's Experience

Author

Chojecki, Aleksander L., primary, Arnall, Justin, additional, Boselli, Danielle, additional, DiSogra, Kristyn Y., additional, Karabinos, Allison, additional, Chen, Tommy, additional, Ai, Jing, additional, Knight, Thomas G., additional, Ragon, Brittany Knick, additional, Shah, Nilay A., additional, Sanikommu, Srinivasa R., additional, Symanowski, James T, additional, Avalos, Belinda R, additional, Copelan, Edward A., additional, and Grunwald, Michael R., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results